Amolyt Pharma

Investment area
Novo Ventures
Region
Europe
Date of investment
July 2019

Amolyt Pharma develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Their ambition is to become a leading rare disease company with U.S. and European operations to support
global development of our products.

Amolyt Pharma

Investment area
Novo Ventures
Region
Europe
Date of investment
July 2019

Amolyt Pharma develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Their ambition is to become a leading rare disease company with U.S. and European operations to support
global development of our products.

Amolyt Pharma

Investment area
Novo Ventures
Region
Europe
Date of investment
July 2019

Amolyt Pharma develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Their ambition is to become a leading rare disease company with U.S. and European operations to support
global development of our products.